Seer Appoints New Chief Medical Officer
Ticker: SEER · Form: 8-K · Filed: Jul 12, 2024 · CIK: 1726445
| Field | Detail |
|---|---|
| Company | Seer, Inc. (SEER) |
| Form Type | 8-K |
| Filed Date | Jul 12, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel, biotech
TL;DR
Seer snagged Verily's ex-CMO, Daniel Spiegel, to lead their medical strategy.
AI Summary
Seer, Inc. announced on July 8, 2024, the appointment of Dr. Daniel R. Spiegel as Chief Medical Officer. Dr. Spiegel previously served as Chief Medical Officer at Verily Life Sciences, an Alphabet company. This appointment is part of Seer's ongoing efforts to advance its proteomic analysis platform.
Why It Matters
The appointment of a new Chief Medical Officer with experience from a major tech-affiliated life sciences company like Verily could signal a strategic push by Seer to integrate its proteomic technology more deeply into clinical applications and research.
Risk Assessment
Risk Level: low — This filing primarily concerns an executive appointment, which is a standard corporate event with no immediate financial implications.
Key Players & Entities
- Seer, Inc. (company) — Registrant
- Dr. Daniel R. Spiegel (person) — Appointed Chief Medical Officer
- Verily Life Sciences (company) — Previous employer of Dr. Spiegel
- Alphabet (company) — Parent company of Verily Life Sciences
FAQ
What is the effective date of Dr. Daniel R. Spiegel's appointment as Chief Medical Officer?
The filing reports the earliest event as July 8, 2024, indicating this is the effective date or the date of the announcement.
What was Dr. Spiegel's role prior to joining Seer, Inc.?
Dr. Spiegel previously served as Chief Medical Officer at Verily Life Sciences.
Is Dr. Spiegel's compensation arrangement detailed in this filing?
The filing indicates 'Compensatory Arrangements of Certain Officers' as an item information, suggesting details may be included or referenced.
What is Seer, Inc.'s primary business?
Seer, Inc. is involved in 'LABORATORY ANALYTICAL INSTRUMENTS' with SIC code 3826.
Where is Seer, Inc. headquartered?
Seer, Inc. is headquartered at 3800 Bridge Parkway, Suite 102, Redwood City, California 94065.
Filing Stats: 755 words · 3 min read · ~3 pages · Grade level 14.2 · Accepted 2024-07-12 16:17:03
Key Financial Figures
- $0.00001 — tered Class A Common Stock, par value $0.00001 per share SEER The NASDAQ Stock Mar
Filing Documents
- ck0001726445-20240708.htm (8-K) — 43KB
- 0000950170-24-083207.txt ( ) — 162KB
- ck0001726445-20240708.xsd (EX-101.SCH) — 30KB
- ck0001726445-20240708_htm.xml (XML) — 5KB
02(b)
Item 5.02(b) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 8, 2024, Rachel Haurwitz, Ph.D. informed Seer, Inc. (the "Company") of her resignation as a member of the Company's Board of Directors (the "Board") and all committees thereof, effective immediately (the "Director Resignation"). On July 11, 2024, the Company notified The Nasdaq Stock Market LLC ("Nasdaq") that upon the effectiveness of the Director Resignation, the Company will no longer be in compliance with the Nasdaq Listing Rule 5605(c)(2)(A), which requires that (i) the Audit Committee of the Board (the "Audit Committee") be composed of at least three members, and (ii) that one member of the Audit Committee has past employment experience in finance or accounting, requisite professional certification in accounting, or any other comparable experience or background which results in the individual's financial sophistication, including being or having been a chief executive officer, chief financial officer or other senior officer with financial oversight responsibilities. Due to the vacancy on the Audit Committee that will exist as a result of the Director Resignation, the Company intends to rely on the cure period provided by the Nasdaq Listing Rule 5605(c)(4)(B). The Company is evaluating the appropriate membership and composition of its Board and Board committees and intends to regain compliance with the Nasdaq Listing Rule 5605(c)(2)(A) prior to the expiration of the applicable cure period granted under the Nasdaq Listing Rule 5605(c)(4)(B).
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties. Such forward-looking statements are based on the Company's beliefs and assumptions and on information currently available to it on the date hereof. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in the Company's other filings with the Securities and Exchange Commission, including the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents the Company files with the Securities and Exchange Commission from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SEER, INC. Date: July 12, 2024 By: /s/ David Horn David Horn President and Chief Financial Officer